Q-Line Biotech IPO Date, Review, Price, Allotment Details

Q-Line Biotech IPO open date is 2026 and the IPO will close on 2026. Q-Line Biotech IPO is a Book build Issue. The company to raise around ₹[.] crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to [.] equity shares with face value of ₹10 each.

Q-Line Biotech IPO price band is ₹[.] to ₹[.] per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Q-Line Biotech IPO to list on NSE on 2026. The allotment of Q-Line Biotech IPO date is 2026.

The company reported revenue of ₹322.58 crores in 2025 against ₹206.45 crores in 2024. The company reported profit of ₹28.13 crores in 2025 against profit of ₹34.44 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

Q-Line Biotech IPO

Q-Line Biotech IPO Details

IPO Open Date2026
IPO Close Date2026
Face Value₹10 Per Equity Share
IPO Price Band₹[.] to ₹[.] Per Share
Issue SizeApprox ₹[.] Crores, 70,53,200 Equity Shares
Fresh IssueApprox ₹[.] Crores, 70,53,200 Equity Shares
Issue TypeBook build Issue
IPO ListingNSE SME
DRHP Draft ProspectusPDF
RHP Draft ProspectusPDF

Q-Line Biotech IPO Review & Key Points

  • Review:

Q-Line Biotech IPO Market Lot

The Q-Line Biotech IPO minimum market lot is [.] shares with ₹[.] application amount.

ApplicationLot SizeSharesAmount
Retail Minimum₹-
Retail Maximum₹-
S-HNI Minimum₹-
S-HNI Maximum₹-
B-HNI Minimum₹-

IPO Reservation

Investor CategoryShare Offered Shares (%)
Anchor Investor– Shares-%
QIB (Ex. Anchor)– Shares50%
NII Shares Offered– Shares15%
Retail Shares Offered– Shares35%

Q-Line Biotech IPO Anchor Investors

Anchor Bidding Date2026
Anchor Investors ListPDF
Shares Offered[.] Shares
Anchor Size[.] Cr.
lock-in period end date 50% shares (30 Days) 2026
lock-in period end date 50% shares (90 Days) 2026

Q-Line Biotech IPO Dates

The Q-Line Biotech IPO date is 2026 and the close date is 2026. The Q-Line Biotech IPO allotment will be finalized on 2026 and the IPO listing on 2026.

IPO Open Date:2026
IPO Close Date:2026
Basis of Allotment:2026
Refunds:2026
Credit to Demat Account:2026
IPO Listing Date:2026
IPO Bidding Cut-off Time:2026 – 5 PM

Promoters and Holding Pattern

The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.

ParticularShares% Share
Promoter Holding Pre Issue1,62,74,999-%
Promoter Holding Post Issue-%

Objects of the Issue & Utilisation of Proceeds

PurposeCrores
To meet Working Capital requirements₹110.00
Repayment of certain borrowing availed by the Company, in part or full₹90.00
General Corporate Purpose₹-

About Q-Line Biotech IPO

Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range. 

Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.

Q-Line Biotech IPO Company Financial Report

Amount ₹ in Crores

Period EndedRevenueExpensePATAssets
2023₹184.81₹154.97₹32.10₹251.58
2024₹206.45₹175.85₹34.44₹339.25
2025₹322.58₹261.43₹28.13₹455.49

Q-Line Biotech IPO Valuation – FY2025

Check Q-Line Biotech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPIValues
ROE:17.66%
ROCE:23.74%
EBITDA Margin:22.73%
PAT Margin:8.97%
Debt to equity ratio: 0.87
Earning Per Share (EPS):₹28.63 (Basic)
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):23.74%
Net Asset Value (NAV):₹120.60

Peer Group Comparison

There are no listed companies in India.

IPO Lead Managers aka Merchant Bankers

  • Hem Securities Ltd.
  • Share India Capital Services Pvt. Ltd.

Company Address

Q-Line Biotech Ltd.
298-281,
Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/

IPO Registrar

Purva Sharegistry (India) Pvt.Limited.
Phone: +91-022-23018261/ 23016761
Email: support@purvashare.com
Website: https://www.purvashare.com/investor-service/ipo-query

Q-Line Biotech IPO FAQs

What is Q-Line Biotech IPO?

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹[.] Crores via IPO. The issue is priced at ₹[.] to ₹[.] per equity share. The IPO is to be listed on NSE.

When Q-Line Biotech IPO will open for subscription?

The IPO is to open on 2026 for QIB, NII, and Retail Investors. The IPO will close on 2026.

What is Q-Line Biotech IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Q-Line Biotech IPO?

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is Q-Line Biotech IPO Issue Size?

Q-Line Biotech IPO issue size is ₹[.] crores.

What is Q-Line Biotech IPO Price Band?

Q-Line Biotech IPO Price Band is ā‚¹[.] to ₹[.].

What is Q-Line Biotech IPO Lot Size?

The minimum bid is [.] Shares with ₹[.] amount.

What is the Q-Line Biotech IPO Allotment Date?

Q-Line Biotech IPO allotment date is 2026.

What is the Q-Line Biotech IPO Listing Date?

Q-Line Biotech IPO listing date is 2026. The IPO is to list on NSE.

Note: The Q-Line Biotech IPO price band and date are officially announced. The (Q-Line Biotech IPO grey market premium) will be added to the IPO GMP page as it will start).

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

Leave a Reply

Your email address will not be published. Required fields are marked *